Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
SPYM vs XBI: how they differ
SPYM and XBI hold 2% of their weight in the same names, and XBI returned more over the year.
State Street(R) SPDR(R) Portfolio S&P 500(R) ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, SPYM and XBI hold 2% of their money in the same securities at the same weight.
| Holding | SPYM | XBI |
|---|---|---|
| ABBVIE INC | 0.69% | 1.09% |
| AMGEN INC | 0.32% | 1.09% |
| GILEAD SCIENCES INC | 0.27% | 1.15% |
| VERTEX PHARMACEUTICALS INC | 0.20% | 1.14% |
| REGENERON PHARMACEUTICALS | 0.12% | 1.27% |
| SSI US GOV MONEY MARKET CLASS | 0.07% | 0.08% |
| MODERNA INC | 0.07% | 2.87% |
| BIOGEN INC | 0.05% | 1.07% |
| INCYTE CORP | 0.03% | 1.13% |
| US DOLLAR | 0.28% | 0.02% |
| Only in SPYM | Only in XBI |
|---|---|
| NVIDIA CORP 8.07% | TWIST BIOSCIENCE CORP 1.81% |
| APPLE INC 7.32% | HALOZYME THERAPEUTICS INC 1.47% |
| MICROSOFT CORP 5.58% | NATERA INC 1.46% |
| AMAZON.COM INC 3.76% | KYMERA THERAPEUTICS INC 1.45% |
| ALPHABET INC CL A 2.98% | TRAVERE THERAPEUTICS INC 1.40% |
| BROADCOM INC 2.61% | ROIVANT SCIENCES LTD 1.39% |
| ALPHABET INC CL C 2.38% | ORUKA THERAPEUTICS INC 1.38% |
| META PLATFORMS INC CLASS A 2.16% | REVOLUTION MEDICINES INC 1.36% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | State Street |
| What it is | S&P 500 | SPDR S&P Biotech |
| Total return, 1 year | +17.6% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +0.1 pts | +46.5 pts |
| Expense ratio | 1.30% | 0.35% |
| Already in the S&P 500 | 100.0% | 8.5% |
| Holdings | 507 | 154 |
SPYM in plain words
SPYM is an index equity fund tracking the S&P 500. Over the year to Sep 11, 2026 it returned +17.6% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 1.30% a year. By its holdings filed for Sep 10, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 507 positions, with the top ten at 38.1%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, SPYM or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, SPYM returned +17.6% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, SPYM or XBI?
- SPYM charges 1.30% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do SPYM and XBI overlap with the S&P 500?
- By their latest filed holdings, 100% of SPYM and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, SPYM against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/spym-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources